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Introduction: The Evaluation of the epidermal growth factor
receptor (EGFR) Mutation status for the administration of EGFR-
Tyrosine Kinase Inhibitors in non-small cell lung Carcinoma
(NSCLC) (ERMETIC) project part 1 assessed the accuracy of
EGFR and KRAS mutations detection in NSCLC among 15
French centers.
Methods: The 15 ERMETIC centers selected 74 NSCLC surgical
specimens from previously untreated patients. Paraffin and paired
frozen DNA were sequenced for EGFR exons 18 to 21 and KRAS
exon 2 by an external molecular laboratory, yielding a gold standard.
The 74 blinded paraffin DNAs were redistributed to the 15
ERMETIC laboratories for sequencing of a total of 5550 exons.
Results were compared with the gold standard and between centers
by discordance rates and kappa statistics.
Results: The gold standard included 39 mutated samples with 22
EGFR and 17 KRAS mutated samples. Kappa statistics showed that
10, 6, and 6 of the 15 ERMETIC centers had a moderate to good
kappa score, when compared with external laboratory for EGFR
exon 19, EGFR exon 21, and KRAS exon 2, respectively. Kappa
statistics showed moderate score between centers which increased to
good for EGFR exon 19 mutation when removing 16 poor-quality
samples with high nonamplificable rates.
Conclusions: Paraffin-embedded specimens may represent a suit-
able source of DNA for sequencing analyses in ERMETIC
centers. EGFR exon 19 deletions were most accurately detected
by ERMETIC centers. Ease and accuracy of results, depended more
on the quality of sample than on the difference in molecular
sequencing procedures between centers, emphasize the need of
preanalytical quality control programs.
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Primary lung cancer accounts for the highest number ofcancer deaths worldwide,1 with, a 5-year survival between
10 and 15% in France.2,3 More than 80% of lung cancers are
non-small cell lung cancer (NSCLC), which are subdivided
into squamous cell carcinoma (SCC), adenocarcinoma
(ADC), and large cell carcinoma.4
In ADC, epidermal growth factor receptor (EGFR) is
found to be mutated in 10 to 15% tumors from white patients5
and in more than 40% of tumors from Asian patients.6
Inhibiting EGFR signaling using tyrosine kinase inhibitors
(TKIs), gefitinib or erlotinib, is an effective treatment for
patients with tumors expressing EGFR-sensitizing muta-
tions.7–10 Molecular selection should be performed because
clinical characteristics were shown to be insufficient to accu-
rately select patients harboring EGFR mutations and because
EGFR-TKI resistance may be conferred by mutations in
KRAS (30% of ADC cases) or in EGFR exon 20.11,12
Many diagnostic methods are available for EGFR and
KRAS mutation analysis, but standardized procedures are
lacking,13 although gefitinib recently obtained restrictive Eu-
ropean Medicines Agency/Food and Drug Administration
approval for first-line treatment of patients with EGFR mu-
tated NSCLC.14 In 2005, the French National Cancer Institute
granted a nationwide 2-years multicenter prospective project
to address the standardization of mutation analysis. The
project entitled Evaluation of the EGFR Mutation status for
the administration of EGFR-TKIs in NSCLC (ERMETIC)
involves 15 French clinical/pathological/biological centers.
The project has three consecutive objectives: (i) validate the
widespread use of sequencing as a screening method for
EGFR and KRAS molecular diagnosis on fixed paraffin-
embedded tissues; (ii) select and rank clinical, pathological,
and biological predictors of EGFR-TKI response and clinical
benefit in a large prospective clinical cohort; and (iii) deter-
mine the most cost-effective strategy to prescribe EGFR-
TKIs, i.e., based on EGFR biomarkers. This study focuses on
part 1 of the ERMETIC project.
PATIENTS AND METHODS
The ERMETIC project part 1 was subdivided into two
phases, phase A and phase B. The phase A addressed the
question of the discordances that could be observed between
results of paraffin and frozen samples. It consisted in the
comparison of direct sequencing analysis of paraffin-embed-
ded samples from 74 patients with NSCLC and their snap-
frozen counterparts by an external molecular laboratory (P.
Hainaut, IARC, Lyon, France). The phase B addressed the
cross-validation of paraffin-embedded samples analysis
among the 15 ERMETIC French molecular laboratories.
Description of the ERMETIC Tumor Bank
Each of the 15 ERMETIC centers selected 1 to 10
NSCLC surgical specimens from previously untreated pa-
tients, according to French regulations. For each deidentified
specimen, a fixed paraffin-embedded block containing more
than 50% tumor cells and a snap-frozen counterpart was
required. Samples were selected for clinical features linked to
a high probability of EGFR mutation: female, ADC, and
nonsmoker.6 Each center also selected one patient with SCC,
with a high probability of being wild type for EGFR and
KRAS. Tumor paraffin blocks were sent to the coordination
center for centralized review by three pathologists (M.A.,
E.B., and C.D.) based on 2004 World Health Organization
classification and to determine the proportion of tumor cells
assessed on a slide performed at the end of block sections and
stained by hematoxylin-eosin-safran coloration.
DNA Preparation
Each ERMETIC centers prepared, without macrodissec-
tion, 16  3 sections (15 m thick) from their own paraffin
blocks to perform 16 extractions for each sample. All centers
extracted DNA using similar principles, i.e., affinity-column-
based protocols excepted for two centers using protocols based
on magnetic particles, with extraction controls (water) in each
series (see supplementary data, http://links.lww.com/JTO/A89;
Table Si, http://links.lww.com/JTO/A90). DNAs from the 16
extractions were pooled. The median quantity of pooled
DNA by sample was 13 g (range: 0.7–127 g) by Nano
Drop (Wilmington, DE) (see supplementary data, Table
Sii, http://links.lww.com/JTO/A91). Quality of pooled DNA
samples was evaluated by a ladder amplification tech-
nique analysis15 (see supplementary data, Table Sii,
http://links.lww.com/JTO/A91). The 74 pooled DNA sam-
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ples were shipped to the coordination center to be aliquoted,
blinded, and redistributed to each of the 15 ERMETIC centers,
which received the same quantity (1/16 of pooledDNA samples) of
the extracted DNA for each sample.
Pooled DNA extracts from paraffin samples and snap-
frozen paired specimens were also sent to the external mo-
lecular laboratory (P. Hainaut, IARC, Lyon, France).
Sequencing Procedure
Sequencing was performed in the external molecular
laboratory as described previously16 and in the 15 different
ERMETIC centers by using their own procedures and internal
quality controls (see supplementary data, Table Siii,
http://links.lww.com/JTO/A92). A common decision algo-
rithm was adopted (M.B.-F., A.D., V.B., F.C., and J.-L.P.),
including a minimum of three polymerase chain reaction
(PCR) amplification attempts for each exon, before a sample
was considered nonamplificable (NA). All mutations had to
be detected in both strands and confirmed by sequencing
analysis of a second, independent PCR product. Each ER-
METIC center sequenced EGFR (exon 18–21) and KRAS
(exon 2) genes in all blinded paraffin DNA extracts, and the
external molecular laboratory sequenced EGFR and KRAS
genes in all paraffin and paired snap-frozen DNA samples, to
provide a gold standard reference value. Centers used direct
or nested sequencing, but each used their own standard
procedure to reflect the different center molecular procedures.
Therefore, testing was done as if the different laboratories
had to analyze the samples in routine diagnosis.
Frozen samples were used as the gold standard because
unfixed samples have a lower risk of DNA artifacts.17 For six
samples, frozen tissue was not proper (absence or 30% of
tumor cells) to be used as the gold standard. For those six
samples, more sensitive molecular techniques were performed
on fixed paraffin-embedded samples: for KRAS, KRAS Ther-
ascreen DxS kit (DxS, Manchester, UK) (A.D.), peptide-nucle-
ic-acid (PNA)-mediated PCR clamping18 (Eurogentec, Lie`ge,
Belgium) (M.B.-F.), allele-specific oligonucleotide PCR
(N.R.), Taqman allelic discrimination19 (H.B.) and for EGFR,
fragment size separation for insertions/deletions of exon 19
(M.B.-F., A.D., and H.B.) and PCR-restriction fragment
length polymorphism (RFLP) for L858R (A.D. and H.B.).20
These assays were also used to document discrepancies
between the external laboratory and ERMETIC centers for a
few samples that were found mutated by ERMETIC centers
and wild type (WT) by the external laboratory.
Data Collection/Nomenclature
Mutations were described using nomenclature of the Human
Genome Variation Society (http://www.hgvs.org/mutnomen/). Un-
known variants (UVs) were classified as mutations not de-
scribed in the database at the time of analysis. All results
were reviewed by two molecular biologists to identify ambi-
guities in nomenclature (M.B.-F. and A.D.). Each centers
completed a questionnaire to inventory their “Materials and
Methods.”
Statistical Analysis
The sample size was determined to have a specific
precision on the estimated discordance rate between DNA
sequencing from paraffin-embedded samples and snap-frozen
samples. For a confidence interval of a width of 10% around
an expected discordance rate of 15%, at least 49 samples
were requested. This number was increased to 74 samples to
anticipate frozen specimens with too few tumor cells to
perform DNA sequencing and the addition of samples with
SCC histology. Discordances between paraffin and frozen
samples were addressed. A false-positive result was defined
as presence of a mutation in paraffin and WT in paired frozen
sample/gold standard (see “Results” section). A false nega-
tive was defined as WT in paraffin and presence of a mutation
in paired frozen sample/gold standard (see “Results” section).
Paraffin-embedded and frozen sample DNA analyses were
compared by discordance rates, i.e., proportion of false-
positive and false-negative results. Discordance was not de-
fined if one of the samples was NA. Each center was com-
pared with the external molecular center using a standard
kappa statistic. Reproducibility of paraffin-embedded sample
analysis among the 15 centers was assessed using a global
kappa test.21 According to Landis and Koch classification,22
concordance was considered bad if kappa was less than 0.20,
poor if kappa was 0.20–0.40, moderate if kappa was 0.40–
0.60, and good if kappa was greater than 0.60. An exploratory
sensitivity analysis was performed, excluding samples with
high NA rates, i.e., not amplified by half of centers. Statistical
tests were two sided, and p values less than 0.05 were
considered significant.
RESULTS
Clinical and Pathological Characteristics
Clinical and pathological characteristics of the tumor
bank (74 samples) are listed in Table 1. Of the 63 ADC
samples in the tumor bank, 39 (62%) were from nonsmoking
patients of whom 33 (85%) were female. The majority (n 
60; 83%) of paraffin-embedded blocks were less than 5 years
old, and all except three were formalin fixed. In most cases,
paraffin samples had a greater percentage of tumor cells than
paired frozen samples (frozen versus paraffin, Fisher’s exact
test p  0.04).
Phase A: Sequencing of Cryopreserved and
Fixed Paraffin-Embedded Samples by External
Molecular Center
Direct sequencing of EGFR exons 18 to 21 and KRAS
exon 2 was performed by the external molecular laboratory
on blinded tumor DNA extracts from 74 paraffin and 68
paired frozen specimens. Six frozen samples were excluded
as they contained less than 30% tumor cells. Results are
summarized in Table 2 and Figure 1.
Cryopreserved Samples (n  68)
All mutations except four detected in DNA from frozen
samples were previously described (Hope database http://
www.egfr.org and http://www.sanger.ac.uk/genetics/CGP/
cosmic/) (Table 2). EGFR mutations were described in 22
(32%) frozen samples, including three samples with two
EGFR mutations. All 22 EGFR mutated samples were from
females with ADC of whom 19 were never smokers and three
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were current/former smokers. One mutation was found in
exon 18 (G719A), associated with an exon 21 mutation
(L861Q). One UV insertion was found in exon 20. Thirteen
samples had a deletion in exon 19 and one also contained an
UV single mutation. Eight samples had a mutation in exon 21
(seven L858R and one L861Q mutations), one also had a
single UV mutation. Two DNA samples were nonamplific-
able (NA) for exon 19. KRAS mutations were found in 14
(21%) ADC samples including 10 females and 4 males of
which nine were current/former smokers and five were never
smokers. All DNA samples were amplifiable for KRAS.
EGFR and KRAS mutations were mutually exclusive.
Fixed Paraffin-Embedded Samples (n  74)
All EGFR and KRAS mutations found in paraffin sam-
ples were also found in the 68 paired frozen samples. No
discordance (see “Patients and Methods” section) was found
in 46 amplified samples for exon 19. A single discordance
(2%) was found in 54 samples amplified for EGFR exon 21
(L858R), and two discordances (4%) were found in 64
samples amplified for KRAS (G12C and G12V) (Table 2).
All discordances were mutations found in frozen but not in
paraffin samples and were classified as three false-negative
results.
DNA was NA from 75 of 370 exons (20%) analyzed
from paraffin samples (Figure. 1). Nine samples accounted
for 39 NA exons (52%), these samples were NA for all four
EGFR exons and three were also NA for KRAS. Of these nine
paraffin samples, five were more than 5 years old, and one
was Bouin fixed.
Analysis of paraffin DNA samples produced very few
false-negative and no false-positive mutations compared with
frozen specimens, so the project progressed to phase B.
Phase B: Sequencing of Blinded Paraffin
Samples by the 15 ERMETIC Centers
Gold Standard
A gold standard was built with results from (1) se-
quencing 68 frozen amplifiable DNA samples and (2) for six
paraffin samples for which the paired frozen sample had less
than 30% tumor cells, at least two more sensitive molecular
techniques (described earlier) were performed, adding three
supplementary KRAS mutations. Sequencing results for the
74 blinded paraffin samples, obtained by each of the 15
ERMETIC centers, were compared with the gold standard.
Descriptive Analysis of Mutations
Figure 2 summarizes the assessment of EGFR and
KRAS mutations in the 15 participating centers. None of the
ERMETIC centers detected the exon 20 EGFR mutation
included in the gold standard (data not shown). Two













65 (39–84) 65 (42–84) 62 (39–80)
Gender
Female 56 (76) 53 (84) 3 (27)
Male 18 (24) 10 (16) 8 (73)
Smoking status
Never smoker 39 (53) 39 (62) 0 (0)
Current/former
smoker








70 (0–100) 70 (0–90) 70 (0–100)
Type of fixation
Formol 71 (96) 60 (95) 11 (100)




5 yr 60 (83) 52 (85) 8 (73)
5 yr 12 (17) 9 (15) 3 (27)
a Age was calculated from the time of tumor sample fixation until May 2006 (date
of ERMETIC bank collection).
ADC, adenocarcinoma; SCC, squamous cell carcinoma; MD, missing data.
TABLE 2. EGFR and KRAS Mutations Identified by the External
Molecular Center in Frozen and Paired Paraffin Samples
Frozen
(n  68) Type of Mutation Paraffin (n  68)
25 EGFR 18
1 EGFR exon 18 mutations 0
1 c.2156G  C, p.Gly719Ala (G719A)a NA
14 EGFR exon 19 mutations 12
5 c.2235_2249del; p.Glu746_Ala750delb 5







1 c.2260A  G; p.Lys754Glu (UV)b 1
1 c.2237_2251del; p.Glu746_Thr751delinsAla 1
1 c.2239_2240TT  CC; p.Leu747Pro (UV) NA
1 c.2239_2256del; p.Leu747_Ser752del 1
1 c.2240_2257del; p.Leu747_Pro753delinsSer 1




9 EGFR exon 21 mutations 6
7 c.2573T  G; p.Leu858Arg (L858R)c 5  1WT  1NA
1 c.2543T  C; p.Pro848Leu (UV)c NA
1 c.2582T  A; p.Leu861Gln (L861Q)a 1
14 KRAS 11
6 c.35G  A; p.Gly012Asp (G12D) 5  1NA
6 c.34G  T; p.Gly012Cys (G12C) 5  1WT
2 c.35G  T; p.Gly012Val (G12V) 1  1WT
a,b,c Presence of a double mutant.
NA, nonamplificable; WT, wild type; UV, unknown variant; EGFR, epidermal
growth factor receptor.
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ERMETIC centers detected the G719A mutation in exon
18 that was included in the gold standard (data not shown).
For exon 19 EGFR analysis, 11 of 13 (85%) mutations in
the gold standard were found by 11 of 15 ERMETIC
centers (Figure. 2). For exon 21 EGFR analysis, only four
of eight (50%) mutations (three L858R and one L861Q), in
FIGURE 2. Phase B, sequencing of 74 blinded paraffin samples by the 15 ERMETIC centers. In abscissa are the 74 samples
and in ordinate the 15 ERMETIC centers. Proportion of mutated, wild type, and nonamplicable DNA specimens are repre-
sented by red, white, and gray bars, respectively. GS, gold standard; ERMETIC, evaluation of the epidermal growth factor re-
ceptor mutation status for the administration of EGFR-tyrosine kinase inhibitor in non-small cell lung carcinoma.
FIGURE 1. Phase A, external molecu-
lar center sequencing of frozen and
paraffin samples. Six frozen tumors
were not available for analysis (black
bars). Proportion of mutated, wild-
type and nonamplifiable DNA speci-
mens are represented by red, white,
and gray bars, respectively.
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the gold standard were found by 14 of 15 ERMETIC
centers (Figure. 2). For KRAS analysis, 7 of 17 (41%) of
mutations in the gold standard were found by 11 of 15
ERMETIC centers (Figure. 2).
False-positive and false-negative mutation results (see
“Patients and Methods” section for definition) by sample,
compared with the gold standard, are listed in Table 3. More
samples harbor false-positive results for EGFR mutations
than false-negative results, and vice versa for KRAS. False-
positive and false-negative mutation results by center are
listed in Table 4. The highest median rate of false-positive
results by center was for EGFR exon 21, whereas KRAS exon
2 showed the highest median rate of false-negative results by
center. In contrast, EGFR exon 19 showed a low median rate
of either false-positive or false-negative results by centers.
Nonamplificable Paraffin Samples
The proportion of NA samples was highly variable
(Figure. 2). Nine samples (12%) were amplified at exon 19,
21 EGFR and KRAS by all ERMETIC centers. The other 65
samples were categorized as slightly (5 centers with
nonamplified samples, n  42, 57%), moderately (5–7 cen-
ters with nonamplified samples, n  7, 9%), and highly (7
centers with nonamplified samples, n  16, 22%) NA for
these three exons. Six centers were found to have the highest
rates of amplification for all three exons. For exon 19, 21
EGFR and KRAS analysis, the percentage of NA samples for
each center was comparable. The median rate of NA samples
was 26% (0–34%) for EGFR exon 18, 19% (0–49%) for
EGFR exon 19, 28% (1–61%) for EGFR exon 20, 20%
(1–43%) for EGFR exon 21, and 15% (4–53%) for KRAS.
Kappa Concordance Statistics
Kappa concordance values were not calculated for
EGFR exons 18 and 20 because they had a very low fre-
quency of EGFR mutations. Kappa concordance statistics
between each of the 15 ERMETIC centers and the gold
standard was performed for EGFR exons 19 and 21, and
KRAS mutation analyses (Table 5). Exon 19 had the highest
concordance value, whereas exon 21 and KRAS had mostly
moderate or poor ratings. Results of global kappa tests for
concordance among the 15 ERMETIC centers are presented
in Table 6. The low level of concordance between centers
may reflect the number of NA DNA samples. A sensitivity
analysis excluding the 16 samples qualified as highly NA
resulted in increased global kappa test scores (Table 6).
DISCUSSION
ERMETIC part 1 is the first nationwide study assessing
in a blinded tumor DNA bank the accuracy of detection of
EGFR and KRAS mutations as molecular biomarkers for
NSCLC EGFR-targeted therapy. At the beginning of the
ERMETIC project (2005), limited information was available
on the frequency and type of EGFR sensitizing or resistance
mutations. DNA sequencing was considered the most effec-
TABLE 3. Results by Sample (n 74): False Positive and False









Number of samples with




Number of samples with




EGFR, epidermal growth factor receptor.
TABLE 5. Kappa Concordance Values: Concordance of
Each ERMETIC Center Sequencing with the Gold Standard
Kappa Score
Rating
Number of Centers with Kappa Score Rating
EGFR Exon 19 EGFR Exon 21 KRAS
Good 9/15 0/15 3/15
Moderate 1/15 6/15 3/15
Poor 4/15 9/15 8/15
Bad 0/15 1/15 2/15
Median Kappa
score (range)
0.52 (0.23–0.73) 0.37 (0.20–0.57) 0.39 (0.15–0.66)
EGFR, epidermal growth factor receptor.
TABLE 4. Results by Center (n15): False Positive and False










Median rate of false-
positive results by
center, (range)
0% (0–27%) 17% (0–37%) 8% (0–25%)
Number of centers with
a false-positive
rate of
0% 9/15 7/15 5/15
0%, 10% 1/15 0/15 4/15
10% 5/15 8/15 6/15
False-negative results
Median rate of false-
negative results by
center, (range)
2% (0–9%) 3% (0–6%) 9% (2–17%)
Number of centers with
a false-negative
rate of
0% 6/15 6/15 0/15
0%, 10% 9/15 9/15 8/15
10% 0/15 0/15 7/15
EGFR, epidermal growth factor receptor.
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tive approach to acquire detailed, specific, and comparable
information. Therefore, international experts designated
by the French National Cancer Institute to evaluate the
ERMETIC project, recommended that external molecular
laboratory, as well as ERMETIC centers, performed direct
sequencing.
The external molecular laboratory analyzed 74 paraffin
embedded and 68 paired frozen samples for EGFR and KRAS
mutations (phase A). Our study verifies the current database
of known EGFR single-base mutations (G719A in exon 18,
and L858R and L861Q in exon 21) and known insertion/
deletions in exons 19 and 20.6 No false-positive results and
only three false-negative results were identified when paraffin
samples were compared with paired frozen samples. Detec-
tion of EGFR and KRAS mutations can, therefore, be accu-
rately performed using paraffin-embedded tissues prepared
for routine diagnosis. In addition, the use of these materials
makes it possible to verify the presence of tumor cells and to
select areas containing a high proportion of tumor cells in
cases with low tumor cells (macrodissection).
Progressing into a nationwide study, the project was to
compare EGFR and KRAS mutation sequencing results from
15 ERMETIC centers with the gold standard (phase B). In
phases A and B of the ERMETIC project, NA DNA was the
main difficulty resulting from the use of paraffin-embedded
samples and also the major source of variation among results
observed between ERMETIC centers. Interestingly, the NA
samples often originated from the same centers, and the DNA
extracted from these samples was often difficult to amplify
for all exons analyzed (Table Sii). Four factors seem to be
critical. The first one is the fixation procedure. The presence
of trace of additives in fixatives such as Bouin’s is known to
inhibit the PCR amplification reactions, as found for three
samples from one center (Table 7). Over fixation with for-
malin-based fixative may also induce DNA fragmentation
and cross-linking, preventing DNA amplification and might
explain some difficulty of PCR reactions in some samples
from other different centers. Nevertheless, duration of fixa-
tion did not affect the rate of amplification failure in our
study. Furthermore, length of amplificated DNA fragments,
which are related to DNA quality, appeared smaller in the
highly nonamplicable samples (Table 7). The second factor is
the age and conditions of storage of the tissue block, which
may result in DNA oxidation and fragmentation. Indeed, five
of our nine (55%) higher nonamplificable samples were more
than 5 years old (Table 7). As all tissue blocks were stored at
room temperature, in all the ERMETIC centers, amplification
failure was not related to conditions of storage. The third
factor is the DNA extraction procedure, which may not yield
sufficient amounts of DNA and/or introduce traces of re-
agents that impair PCR reactions. The use of xylene for DNA
extraction seems to induce more difficulties for DNA ampli-
fication for several ERMETIC centers (Table 7). Although
DNA concentrations seemed higher in successfully amplifi-
cated cases, there was no statistically significant differences
in the levels of DNA concentration between the different
categories of amplification failure (see “Results” section for
definition) (Table 7). Although our data did not show any
significant relationship between poor DNA quality extraction
and amplification failure, this question may be addressed
using newer generation mutation analysis techniques in an
ongoing second ERMETIC project. Finally, ease of DNA
amplification also depends on the amplicon size. Among the
five exons analyzed, exon 20 amplicon had the highest size in
13 of 15 centers, may be explaining that this exon was
responsible for the highest rate (311/1110, 28%) of amplifi-
cation failure (data not shown). Furthermore, rate of nonampli-
ficable cases seemed related to higher length of amplicons, for
EGFR exons 19 and 21, as well as for exon 2 KRAS (Table 8).
False-negative results were observed in nine centers for
EGFR exons 19 and 21 and in all the centers for KRAS. The
mutations were identified by sequencing analysis sensitivity
of which is known to be approximately 25% of mutated
cells,13 and therefore, all evaluated paraffin samples should
contain more than 50% of tumor cells. This low sensitivity of
sequencing makes this technique probably inadequate for
analysis of low proportion of tumor cell samples and may
have resulted in some false-negative results.13 In our study,
only 1 of 12 false-negative KRAS mutated samples (found
falsely negative by eight centers) contained less than 40% of
tumor cells. Other reasons should be hypothesized. DNA
extraction procedure could be involved as extraction with
xylene presented the highest percentage of false-negative
results (Table 7). The mutation type may also have affected
detection rates, as EGFR exon 19 deletions are easier to
detect than point mutations in exon 21 or in KRAS exon 2.
Interestingly, in DNA from paraffin-embedded samples, de-
leted fragments could be selected in the amplification proce-
dure, whereas single-base mutations (EGFR exon 21 or
KRAS) were not, an observation that would point out a
different rate of mutant allele amplification efficacy on DNA
altered by the fixative. This might also explain why KRAS
analysis was so difficult for many centers. This problem may
be addressed by implementing more sensitive, mutant allele-
specific detection techniques.
The clinical consequence of inaccurate detection of
EGFR or KRAS mutations is an important consideration
because patients would potentially receive inappropriate
treatments. False-positive detection of EGFR-activating mu-
tations could lead to counter-productive patient treatment
with EGFR-TKIs, as recently demonstrated in the Asian
IPASS phase III trial.10 Critically, patients whose tumors
TABLE 6. Kappa Concordance Values: Concordance
between the 15 ERMETIC Centers
Samples
Compared
Global Kappa Score (95% CI)
EGFR Exon 19 EGFR Exon 21 KRAS
All samples
(n  74)




0.60 (0.58–0.61) 0.56 (0.55–0.58) 0.47 (0.45–0.49)
a Sensitivity analysis was performed, excluding 16 samples with high nonamplifi-
able rates, i.e., not amplified by half of centers.
EGFR, epidermal growth factor receptor.
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were EGFR wild type had a marked decline in PFS compared
with those who received chemotherapy (hazard ratio: 2.85;
95% confidence interval: 2.05–3.98; p  0.001).10 In con-
trast, false-positive detection of KRAS mutations may prevent
patients from receiving effective EGFR-TKIs. Nevertheless,
the prognostic and predictive significance of KRAS mutations
in the context or EGFR-TKI therapy are still a matter of
debate. The frequency of false-positive results varied be-
tween centers, samples, and also exons (Table 3). One
ERMETIC center using toluene reagent for its DNA extrac-
tion procedure was responsible for at least one false-positive
result of EGFR exon 19, EGFR exon 21, and KRAS mutation
by four, one, and two centers, respectively. All centers used
more than 20 ng of DNA for sequencing analysis, suggesting
that false-positive results did not come from rate-limiting
amount of DNA template. By contrast, the rate of false-
positive results was highest in highly and moderately nonam-
plificable samples (14/23 [61%] versus 8/51 [15%] for others;
p  0.01). Technical explanation could be proposed for the
three centers having the highest false-positive rate for EGFR
exon 19 deletions with two centers using more than 40 PCR
cycles and the other one using a nested PCR (Table Siii). Two
other centers were responsible from all five L858R EGFR
exon 21 false-positive mutations suggesting DNA contami-
nation. Finally, among 13 false-positive EGFR exon 21
mutations, five are transition type of whom three related to
highly nonamplificable samples.17
As mutation analysis was based on low-sensitive se-
quencing technique in the ERMETIC project—part 1, two
samples with “false-positive” results found by ERMETIC
centers were finally confirmed mutations, by alternative more
sensitive techniques. These results concerned one sample
with L858R EGFR mutation found by two centers and wild
type by the 13 other centers, and one sample with G12S
KRAS mutation found by nine centers, wild type by five
centers, and nonamplificable by one center. These low-signal
mutants could be subclones in the tumor, similar to the
T790M EGFR resistance mutation or KRAS mutation previ-
ously described in tumoral subclones.23–25
Finally, despite a relative heterogeneity in sequencing
procedures, there was moderate agreement in mutation detection
TABLE 7. Paraffin Blocks Characteristics and DNA Quantity/Quality Findings in Relationship with the Rate of Amplification










Cases (n  22)
False-Negative
Cases (n  22)
Blocks characteristics
Fixation procedure (n)
Formalin 13 7 42 9 21 21
Bouin 3 0 0 0 1 1
Cell count (%), median (range) 70 (30–90) 80 (40–90) 80 (40–90) 80 (50–90) 70 (30–90) 70 (40–90)
Age of block (yr), median (range) 5 (0.8–15.6) 4 (1.2–5) 2.8 (0.4–6.7) 1 (0.1–4.5) 4 (0.8–15.6) 2.7 (0.1–15.6)
Time of fixation
48 h, n (%) 10 (62) 3 (43) 29 (69) 4 (44) 14 (64) 13 (59)
48 h, n (%) 6 (38) 4 (57) 13 (31) 5 (56) 8 (36) 9 (41)
Extraction, n (%)
Heating 5 (31) 2 (29) 21 (50) 6 (67) 7 (32) 5 (23)
Scrapping 2 (12.5) 0 (0) 3 (7) 3 (33) 3 (14) 4 (18)
Toluene 1 (6) 2 (28) 6 (14) 0 (0) 7 (32) 4 (18)
Xylene 8 (50) 3 (43) 12 (28) 0 (0) 5 (22) 9 (40)
DNA quantity/quality
Concentration (ng/l), median (range) 93.5 (18–270) 88 (8–260) 64 (3–1274) 101 (65–573) 53 (3–223) 64 (3–430)
260/280 ratio, median (range) 1.79 (1.65–2.22) 1.84 (1.4–1.92) 1.99 (1.78–2.08) 1.95 (1.92–2.06) 1.79 (1.55–2.22) 1.95 (1.63–2.22)
Ladder (bp), median (range) 80 (80–200) 100 (100–200) 200 (200–300) 300 (300–300) 100 (80–200) 200 (80–300)
H-NA, highly nonamplificable; M-NA, moderately nonamplificable; S-NA, slightly nonamplificable; A, amplificable (as defined in “Results” section, in “NA paraffin samples”
section).
TABLE 8. Amplicon Size in Relationship with the








EGFR exon 19 20.5 0 0
EGFR exon 21 16 22.2 0
KRAS 16 7.8 8
Amplicon size
160 pb, 300 bp
EGFR exon 19 19.6 8 3
EGFR exon 21 19.5 11.25 2.65
KRAS 21 11.7 10.2
Amplicon size
300 pb
EGFR exon 19 31.8 9.78 3.86
EGFR exon 21 21.5 8.75 2.35
KRASa — — —
a KRAS analysis, no amplicon was higher than 300 bp.
NA, nonamplificable; bp, base pairs; EGFR, epidermal growth factor receptor.
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between the centers and the gold standard, and among the
centers, as indicated by global kappa values. Nevertheless, if
poor-quality samples/DNA were excluded from statistical anal-
yses (i.e., Bouin fixed, 5 years old and toluene extracted),
global kappa values were clearly improved, reflecting the true
level of agreement between centers.
In conclusion, our results indicate that paraffin-embedded
specimens may represent a suitable source of DNA for sequenc-
ing analyses in ERMETIC centers. Nevertheless, ease and ac-
curacy of results obtained depended more on the quality of
samples and DNA extraction, as well as on the type of exon than
the difference in molecular sequencing procedures between
centers. This emphasizes the need for rigorous stepwise quality
control programs including preanalytic recommendations, to
ensure accurate detection of biomarkers for EGFR-targeted
therapies. It will be true not only for direct sequencing but also
for screening mutations by newer generation analysis techniques
for which the role of DNA extractions might be also important.
Finally, sequencing is probably not enough sensitive to be
applied in a routine diagnostic strategy of EGFR mutations
performed on poor-quality DNA samples, as in particular for
small biopsy samples that often contains less than 50% of tumor
cells. This question will be addressed in the second step of the
ERMETIC project, which will test for biomarkers in response to
EGFR-TKIs in a prospective cohort of more than 500 patients
including 70% with the small paraffin-embedded NSCLC bi-
opsy samples.
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